ARGX — ARGENX SE catalysts
Next verified catalyst
2026-08-01 — A Study to Evaluate the Clinical Outcomes of Efgartigimod PH20 SC in Adults With New-onset · official source ↗
Upcoming
| Date | Event | Company | Drug | Official source & verification |
|---|---|---|---|---|
| 2026-08 (month) in 1mo
ESTIMATED |
READOUT
A Study to Evaluate the Clinical Outcomes of Efgartigimod PH20 SC in Adults With
Phase 4 · New Onset Generalized Myasthenia Gravis (gMG) |
ARGX ARGENX SE | Efgartigimod PH20 SC |
ClinicalTrials.gov ↗
✓ Source-checked 2026-06-22
Sponsor-projected date — can change
|
| 2026-09 (month) in 2mo
ESTIMATED |
READOUT
A Study to Assess the Efficacy and Safety of Empasiprubart Versus IVIg in Adults
Phase 3 · Multifocal Motor Neuropathy (MMN), MMN |
ARGX ARGENX SE | Empasiprubart, IVIG (Intravenous Immunog |
ClinicalTrials.gov ↗
✓ Source-checked 2026-06-22
Sponsor-projected date — can change
|
| 2026-09-30 in 3mo
ESTIMATED |
READOUT
A Study of Efgartigimod PH20 SC in Children Between 2 and Less Than 18 Years of
Phase 2/3 · Generalized Myasthenia Gravis |
ARGX ARGENX SE | Efgartigimod PH20 SC |
ClinicalTrials.gov ↗
✓ Source-checked 2026-06-22
Sponsor-projected date — can change
|
| 2026-10-01 in 3mo
ESTIMATED |
READOUT
A Phase 3 Study to Evaluate the Safety and Efficacy of Efgartigimod PH20 Subcuta
Phase 3 · Primary Immune Thrombocytopenia |
ARGX ARGENX SE | efgartigimod PH20 SC |
ClinicalTrials.gov ↗
✓ Source-checked 2026-06-22
Sponsor-projected date — can change
|
| 2026-11 (month) in 4mo
ESTIMATED |
READOUT
A Study to Evaluate Safety and Efficacy of Empasiprubart in Adults With Dermatom
Phase 2 · Dermatomyositis, Myositis |
ARGX ARGENX SE | Empasiprubart IV |
ClinicalTrials.gov ↗
✓ Source-checked 2026-06-22
Sponsor-projected date — can change
|